MossRehab, led by renowned Dr. Alberto Esquenazi, utilizing BIONIK’s robotic therapy system in new CORE+ Unit to treat patients infected with or recovering from COVID-19
TORONTO & BOSTON–(BUSINESS WIRE)–BIONIK Laboratories Corp. (OTCQB:BNKL) (“BIONIK”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it has donated an InMotion® robotic system to Einstein Healthcare Network’s MossRehab.
The InMotion® system is being utilized within the newly announced CORE+ Unit, a rehabilitation space for patients infected with or recovering from COVID-19 that require inpatient rehabilitation to return to their communities. The CORE+ Unit is in a dedicated section of MossRehab Elkins Park, where patients will have their own rooms, dedicated staff, stringent PPE requirements, and transportation protocols to reduce risk of infection. Admission requirements include being seven days from COVID-19 diagnosis and 72 hours with no fever. It is believed the CORE+ Unit is the first of its kind in the United Sates.
“We’re grateful for BIONIK and their kind gesture of donating an InMotion® robotic therapy system to MossRehab’s CORE+ Unit. Being infected with COVID-19 should not prevent patients from receiving the high-quality therapy they require for recovery, and BIONIK’s technology will help to ensure patients have the best possible opportunity for positive outcomes,” said Dr. Alberto Esquenazi, Chief Medical Officer, MossRehab. “This generous gift highlights how communities can come together to help those most in need. We thank BIONIK and look forward to utilizing InMotion® robotic therapy with our patients.”
MossRehab is the largest provider of physical medicine and rehabilitation in the Philadelphia region, and a member of Einstein Healthcare Network, the largest independent medical center in the Philadelphia region. Led by the renowned Dr. Esquenazi, MossRehab has been recognized as one of the nation’s 10 best rehabilitation hospitals by U.S. News & World Report.
“We are extremely proud to donate an InMotion® robot to MossRehab, and to help patients inflicted with COVID-19 get the critical therapy they need as they seek a return toward normal life within their communities, and support their dedicated healthcare team with their tireless efforts to rehabilitate patients,” said Dr. Eric Dusseux, CEO, BIONIK. “In times like these, it’s important for everyone to band together to best help the people who need it most. Einstein Healthcare Network and MossRehab have long been renowned for the terrific patient care they provide on a daily basis. We’re happy to be able to join in their mission by offering our innovative robotic therapy solutions free of charge.”
InMotion® robotic therapy systems are used regularly in more than 15 countries to help stroke survivors and those with other neurological conditions regain arm movement by training shoulder protraction/retraction, flexion/extension, abduction/adduction, internal/external rotation and elbow flexion/extension. The improved InMotion® therapy was developed according to the principles of motor learning and neuro-plasticity, using AI and measuring 200 times a second the position, the speed and the acceleration of the upper limb. InMotion® therapy guides the patient through specific tasks, aiming to improve motor control of the arm by increasing strength, range of motion and coordination, and assisting with the provision of efficient, effective and intensive sensorimotor therapy. To learn more, please visit www.bioniklabs.com.
About BIONIK Laboratories Corp.
BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the impact on the Company’s business as a result of the Covid-19 pandemic, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.